Pulse completes thyroid study enrollment

• Pulse Biosciences completed enrollment of 100 patients in the PRECISE-BTN clinical study.
• The study evaluates nPulse technology for treating symptomatic benign thyroid nodules.
• The company plans to present preliminary data at an upcoming medical society conference.

Pulse Biosciences (NASDAQ:PLSE) completed enrollment in the PRECISE-BTN clinical study evaluating its nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules.

The company expanded the study from its original 50-patient design to 100 patients, with enrollment completed across three U.S. clinical sites in approximately 12 months.

The first enrolled patient completed the final 12-month follow-up visit in August 2026 at Sarasota Memorial Health Care System in Florida, while the 100th patient was enrolled during the same month.

Pulse Biosciences said it plans to present preliminary PRECISE-BTN data at an upcoming medical society conference, with full results expected after all patients complete their 12-month follow-up visits.

Pulse Biosciences develops medical technologies using proprietary Nanosecond Pulsed Field Ablation energy, including the nPulse technology platform.

The company is evaluating its technology across clinical applications where targeted energy delivery may support minimally invasive procedures.